Disease Synopsis
Overview
Drugs and Clinical Candidates
Clinical Trials (visual)
Clinical Trials (text)
Cell Line Models
Chemistry

Female Cancers - Overview - Disease Synopsis

Drugs & Clinical Candidates


9 drugs have received FDA approval for Female Cancers . Bevacizumab, Bleomycin Sulfate, Mechlorethamine Hydrochloride, Niraparib, Olaparib, Recombinant Human Papillomavirus (HPV) Nonavalent Vaccine, Recombinant Human Papillomavirus (HPV) Quadrivalent Vaccine, Rucaparib camsylate and Thiotepa
251 drugs have a clinical trial registered for Female Cancers.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Clinical Trials


There are 1632 clinical trials for Female Cancers,
873 of which have one or more drug interventions,
759 with no drug intervention.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Cell Line Models


There are 20 Cell Line Models for Female Cancers.

Source: COSMIC
(see details)

Chemistry


There are 1715 Compounds which have been tested in Female Cancers , 1465 <= 500nM potency.

Source: ChEMBL
(see details)

Mappings


Please note the mappings below are based on an imperfect algorithm. If you notice any anomalies please report them to us.

The following terms have been mapped from clinicaltrials.gov mesh condition terms to Female Cancers:
Fallopian Tube Neoplasms
Genital Neoplasms, Female
Peritoneal Neoplasms
Retroperitoneal Neoplasms
Uterine Cervical Neoplasms
Uterine Neoplasms
Vaginal Neoplasms
Vulvar Neoplasms

The following terms have been mapped from cancer.gov to Female Cancers:
Lesions that sometimes lead to anal, cervical, vaginal, or vulvar cancer
Malignant pleural effusion, malignant pericardial effusion, and malignant peritoneal effusion
Ovarian epithelial, fallopian tube, or primary peritoneal cancer. It is used as maintenance therapy in adults who are having a complete or partial response to platinum chemotherapy. It is used in patients with:Advanced disease that has certain germline or somatic mutations in the BRCA1 or BRCA2 gene
Ovarian epithelial, fallopian tube, or primary peritoneal cancer. It is used as maintenance therapy in patients with recurrent disease who are having a complete or partial response to platinum chemotherapy
Ovarian epithelial, fallopian tube, or primary peritoneal cancer. It is used in patients with stage III, stage IV, or recurrent disease. This use is approved for the Avastin brand of bevacizumab
Ovarian epithelial, fallopian tube, or primary peritoneal cancer. It is used:As maintenance therapy in adults with recurrent disease who are having a complete or partial response to platinum chemotherapy
Squamous cell carcinoma of the vulva
Vaginal cancer
Vulvar cancer